CURE.DE vs. GNOM
CURE.DE (VanEck Genomics and Healthcare Innovators UCITS ETF A) and GNOM (Global X Genomics & Biotechnology ETF) are both Health & Biotech Equities funds - CURE.DE tracks the MVIS Global Future Healthcare ESG while GNOM tracks the Solactive Genomics Index. Both are passively managed. Over the past 3 years, CURE.DE returned -2.48%/yr vs -2.76%/yr for GNOM. A 0.64 correlation means they provide meaningful diversification when combined. CURE.DE charges 0.35%/yr vs 0.50%/yr for GNOM.
Performance
CURE.DE vs. GNOM - Performance Comparison
Loading charts...
Different Trading Currencies
CURE.DE is traded in EUR, while GNOM is traded in USD. To make them comparable, the GNOM values have been converted to EUR using the latest available exchange rates.
Returns By Period
In the year-to-date period, CURE.DE achieves a -5.10% return, which is significantly lower than GNOM's 12.83% return.
CURE.DE
- 1D
- 4.01%
- 1M
- 7.19%
- YTD
- -5.10%
- 6M
- -8.94%
- 1Y
- 5.80%
- 3Y*
- -2.48%
- 5Y*
- —
- 10Y*
- —
GNOM
- 1D
- 0.00%
- 1M
- 9.17%
- YTD
- 12.83%
- 6M
- 9.82%
- 1Y
- 56.14%
- 3Y*
- -2.76%
- 5Y*
- -8.75%
- 10Y*
- —
CURE.DE vs. GNOM - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
CURE.DE VanEck Genomics and Healthcare Innovators UCITS ETF A | -5.10% | 5.09% | 0.30% | -6.42% | -4.35% |
GNOM Global X Genomics & Biotechnology ETF | 12.83% | 4.57% | -10.44% | -11.37% | -15.11% |
Correlation
The correlation between CURE.DE and GNOM is 0.64, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.64 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.63 |
Correlation (All Time) Calculated using the full available price history since Sep 8, 2022 | 0.64 |
The correlation between CURE.DE and GNOM has been stable across timeframes, ranging from 0.63 to 0.64 - a consistent structural relationship.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CURE.DE vs. GNOM — Risk / Return Rank
CURE.DE
GNOM
CURE.DE vs. GNOM - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for VanEck Genomics and Healthcare Innovators UCITS ETF A (CURE.DE) and Global X Genomics & Biotechnology ETF (GNOM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CURE.DE | GNOM | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.92 | ||
| Sortino ratioReturn per unit of downside risk | -2.55 | ||
| Omega ratioGain probability vs. loss probability | 1.06 | 1.35 | -0.29 |
| Calmar ratioReturn relative to maximum drawdown | 0.30 | 3.48 | -3.17 |
| Martin ratioReturn relative to average drawdown | 0.68 | 9.37 | -8.69 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| CURE.DE | GNOM | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.29 | 2.21 | -1.92 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | -0.27 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.14 | -0.09 | -0.05 |
Drawdowns
CURE.DE vs. GNOM - Drawdown Comparison
The maximum CURE.DE drawdown since its inception was -34.80%, smaller than the maximum GNOM drawdown of -72.50%. Use the drawdown chart below to compare losses from any high point for CURE.DE and GNOM.
Loading charts...
Drawdown Indicators
| CURE.DE | GNOM | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -34.80% | -72.50% | +37.70% |
Max Drawdown (1Y)Largest decline over 1 year | -19.07% | -16.22% | -2.85% |
Max Drawdown (3Y)Largest decline over 3 years | -29.32% | -47.28% | +17.96% |
Max Drawdown (5Y)Largest decline over 5 years | — | -70.02% | — |
Current DrawdownCurrent decline from peak | -15.66% | -52.17% | +36.51% |
Average DrawdownAverage peak-to-trough decline | -15.12% | -37.66% | +22.54% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.53% | 6.01% | +2.52% |
Volatility
CURE.DE vs. GNOM - Volatility Comparison
The current volatility for VanEck Genomics and Healthcare Innovators UCITS ETF A (CURE.DE) is 5.73%, while Global X Genomics & Biotechnology ETF (GNOM) has a volatility of 7.96%. This indicates that CURE.DE experiences smaller price fluctuations and is considered to be less risky than GNOM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CURE.DE | GNOM | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.73% | 7.96% | -2.23% |
Volatility (6M)Calculated over the trailing 6-month period | 15.20% | 18.53% | -3.33% |
Volatility (1Y)Calculated over the trailing 1-year period | 19.97% | 25.59% | -5.62% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 20.74% | 32.47% | -11.73% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 20.74% | 33.57% | -12.83% |
CURE.DE vs. GNOM - Expense Ratio Comparison
CURE.DE has a 0.35% expense ratio, which is lower than GNOM's 0.50% expense ratio.
Dividends
CURE.DE vs. GNOM - Dividend Comparison
CURE.DE has not paid dividends to shareholders, while GNOM's dividend yield for the trailing twelve months is around 1.29%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
CURE.DE VanEck Genomics and Healthcare Innovators UCITS ETF A | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
GNOM Global X Genomics & Biotechnology ETF | 1.29% | 1.37% | 0.00% | 0.00% | 0.00% | 0.03% | 0.14% |
Frequently Asked Questions
CURE.DE and GNOM have a correlation of 0.64, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, CURE.DE is cheaper at 0.35% per year. The better choice depends on whether you care most about return, fees, risk, or income.
CURE.DE is cheaper with a 0.35% expense ratio, compared with 0.50% for GNOM.
CURE.DE tracks MVIS Global Future Healthcare ESG, while GNOM tracks Solactive Genomics Index. They also come from different issuers: VanEck and Global X. Their fees differ too: 0.35% for CURE.DE and 0.50% for GNOM.
Find the right allocation for CURE.DE and GNOM
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer